Skip to main content

Research Repository

Advanced Search

Community engagement in cutaneous leishmaniasis research in Brazil, Ethiopia, and Sri Lanka: a decolonial approach for global health (2022)
Journal Article
Polidano, K., Agampodi, T., Parton, L., Agampodi, S., Haileselassie, B., Lalani, J., …Zerihun, Z. (2022). Community engagement in cutaneous leishmaniasis research in Brazil, Ethiopia, and Sri Lanka: a decolonial approach for global health. Frontiers in Public Health, 10, https://doi.org/10.3389/fpubh.2022.823844

Cutaneous leishmaniasis (CL) is a parasitic skin disease endemic in at least 88 countries where it presents an urgent, albeit often "neglected" public health problem. In this paper, we discuss our model of decolonial community engagement in the ECLIP... Read More about Community engagement in cutaneous leishmaniasis research in Brazil, Ethiopia, and Sri Lanka: a decolonial approach for global health.

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)
Journal Article
Yiu, Z., Mason, K., Hampton, P., Reynolds, N., Smith, C., Lunt, M., …Warren, R. (2020). Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183(2), 294 - 302. https://doi.org/10.1111/bjd.18981

BACKGROUND: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies.

OBJECTIVES: (i) To assess the relative drug survival of... Read More about Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)..

Factors Influencing Family Burden of Paediatric Patients with Atopic Dermatitis: A Cross-sectional Study (2020)
Journal Article
Xu, X., Van Galen, L. S., Bajpai, R., Koh, M. J., Thng, S., Yew, Y. W., …Car, J. (2020). Factors Influencing Family Burden of Paediatric Patients with Atopic Dermatitis: A Cross-sectional Study. Acta dermato-venereologica, 100(14), Article ARTN adv00212. https://doi.org/10.2340/00015555-3458

Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin condition that affects about 10–20% of children and 2-15% of adults in developed countries (1). In Singapore, the prevalence among children and adolescents is 20.8% (2). Itchiness, the... Read More about Factors Influencing Family Burden of Paediatric Patients with Atopic Dermatitis: A Cross-sectional Study.

Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. (2020)
Journal Article
Pan, S., Tsakok, T., Dand, N., Lonsdale, D. O., Loeff, F. C., Bloem, K., …Study Group, B. (2020). Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 13(2), 400 - 409. https://doi.org/10.1111/cts.12725

Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-line... Read More about Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study..

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. (2019)
Journal Article
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, A. (in press). A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181(6), 1265 - 1271. https://doi.org/10.1111/bjd.17849

BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are ass... Read More about A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis..

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2020). Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 34(4), 467 - 467. https://doi.org/10.1111/jdv.16018

Background
The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.

Objectives
To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and stroke) i... Read More about Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2019). Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), 769 - 778. https://doi.org/10.1111/jdv.16018

BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in pa... Read More about Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study..

Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. (2019)
Journal Article
Mason, K., Williams, S., Yiu, Z., McElhone, K., Ashcroft, D., Kleyn, C., …Griffiths, C. (2019). Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181(2), 256 - 264. https://doi.org/10.1111/bjd.17625

BACKGROUND: The persistence and effectiveness of systemic therapies for moderate-to-severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and e... Read More about Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review..

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. (2019)
Journal Article
Warren, R., Marsden, A., Tomenson, B., Mason, K., Soliman, M., Burden, A., …Smith, C. (in press). Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), 1069 - 1076. https://doi.org/10.1111/bjd.16776

BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin... Read More about Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study..

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2019)
Journal Article
Yiu, Z., Ashcroft, D., Evans, I., McElhone, K., Lunt, M., Smith, C., …Mason, K. (2019). Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180(2), 329 - 337. https://doi.org/10.1111/bjd.17036

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque pso... Read More about Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis (2018)
Journal Article
Dand, N., Duckworth, M., Baudry, D., Russell, A., Curtis, C. J., Hyuck Lee, S., …Study Group, B. (2019). HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), 2120-2130. https://doi.org/10.1016/j.jaci.2018.11.038

BACKGROUND: Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treat... Read More about HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. (2018)
Journal Article
Mason, K. (2018). Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154(5), 581 - 588. https://doi.org/10.1001/jamadermatol.2018.0183

Importance: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but... Read More about Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR..

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2017)
Journal Article
Iskandar, I. Y., Warren, R. B., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Griffiths, C. E. (2018). Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(4), 775 - 784. https://doi.org/10.1016/j.jid.2017.09.044

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse event... Read More about Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..

'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis (2013)
Journal Article
Nelson, P. A., Barker, Z., EM Griffiths, C., Cordingley, L., & Chew-Graham, C. A. (2013). 'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Family Practice, 158 -?. https://doi.org/10.1186/1471-2296-14-158

BACKGROUND: Psoriasis is a chronic, inflammatory skin disease affecting approximately 2% of the UK population and is currently incurable. It produces profound effects on psychological wellbeing and social functioning and has significant associated co... Read More about 'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis.